Completed PHASE2 INTERVENTIONAL 1-arm NCT00006227

Paclitaxel in Treating Patients With Ovarian Stromal Cancer

Phase II Study of Paclitaxel for Ovarian Stromal Tumors as Second-Line Therapy

Sponsor: Gynecologic Oncology Group

Conditions Adult Type Ovarian Granulosa Cell Tumor Ovarian Gynandroblastoma Ovarian Sertoli-Leydig Cell Tumor Ovarian Sex Cord Tumor With Annular Tubules Ovarian Steroid Cell Tumor

Interventions Paclitaxel

Updated 14 times since 2017 Last updated: Feb 18, 2020 Started: Nov 20, 2000 Primary completion: Jul 16, 2016 Completion: Jul 16, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00006227, this PHASE2 trial focuses on Adult Type Ovarian Granulosa Cell Tumor and Ovarian Gynandroblastoma and remains completed. Sponsored by Gynecologic Oncology Group, it has been updated 14 times since 2000, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

14 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2023 — Jul 2024 [monthly]

Completed PHASE2
Dec 2022 — Jan 2023 [monthly]

Completed PHASE2

▶ Show 9 earlier versions

Dec 2021 — Dec 2022 [monthly]

Completed PHASE2
Feb 2021 — Dec 2021 [monthly]

Completed PHASE2
Jan 2021 — Feb 2021 [monthly]

Completed PHASE2
Apr 2020 — Jan 2021 [monthly]

Completed PHASE2
Jun 2018 — Apr 2020 [monthly]

Completed PHASE2
Sep 2017 — Jun 2018 [monthly]

Completed PHASE2
Jun 2017 — Sep 2017 [monthly]

Completed PHASE2

Status: Active Not Recruiting → Completed
Feb 2017 — Jun 2017 [monthly]

Active Not Recruiting PHASE2
Jan 2017 — Feb 2017 [monthly]

Active Not Recruiting PHASE2

First recorded

Nov 2000

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Gynecologic Oncology Group
National Cancer Institute (NCI)

Data source: GOG Foundation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Abington, United States , Allentown, United States , Auburn, United States , Aurora, United States , Baton Rouge, United States , Birmingham, United States , Brooklyn, United States , Camden, United States , Canton, United States , Centralia, United States and 71 more locations